As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.
14 Analysts have issued a Zai Lab Ltd. Unsponsored ADR forecast:
14 Analysts have issued a Zai Lab Ltd. Unsponsored ADR forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | 428 428 |
33%
33%
|
|
| Gross Profit | 267 267 |
31%
31%
|
|
| EBITDA | -234 -234 |
32%
32%
|
|
| EBIT (Operating Income) EBIT | -247 -247 |
30%
30%
|
|
| Net Profit | -213 -213 |
29%
29%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Zai Lab Ltd. is a biopharmaceutical company, which engages in the licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need. Its product pipelines include ZL-2306, ZL-2401, FPA144, ETX2514, and ZL-2301. The company was founded by Samantha Ying Du and Marietta Wu in 2014 and is headquartered in Shanghai, China.
| Head office | Cayman Islands |
| CEO | Ying Du |
| Employees | 1,869 |
| Founded | 2014 |
| Website | www.zailaboratory.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


